会议材料

NBDF 2024 - 国家出血性疾病基金会年会 2024
National Bleeding Disorders Foundation 2024
-
美国 · 亚特兰大

本内容仅供您个人及教育用途。请勿下载或进一步传播。未经版权所有者许可,不得进一步复制或传播

共2条结果
会议壁报
Safety and Efficacy of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants With Severe Hemophilia Without Inhibitors: Results From the Phase 3 BASIS Trial and Ongoing Long-Term Extension Study
Acharya SS, Matino D, Palladino A, Hwang E, McDonald R, Turich Taylor C, Teeter J
NBDF 2024 - 国家出血性疾病基金会年会 2024 | 罕见病 | 血友病 | 友瑞宁
会议壁报
Joint health in participants with hemophilia A and hemophilia B without inhibitors treated with marstacimab from the phase 3 BASIS trial
Mahlangu J, Palladino A, Hwang E, McDonald R, Turich Taylor C, Teeter J
NBDF 2024 - 国家出血性疾病基金会年会 2024 | 罕见病 | 血友病 | 友瑞宁